{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T01:12:30Z","timestamp":1780103550406,"version":"3.54.0"},"reference-count":142,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001501","name":"University Grants Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001501","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Rajiv Gandhi National Fellowship"},{"name":"Jadavpur University, Kolkata"},{"name":"Council of Scientific and Industrial Research (CSIR), New Delhi"},{"name":"Department of Pharmaceutical Technology"},{"name":"Jadavpur University, Kolkata, India"},{"name":"Department of Pharmacy, BITS-Pilani, Hyderabad, India"},{"name":"UGC, New Delhi"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1016\/j.ejmech.2018.08.081","type":"journal-article","created":{"date-parts":[[2018,8,29]],"date-time":"2018-08-29T15:36:42Z","timestamp":1535557002000},"page":"1127-1142","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":66,"special_numbering":"C","title":["HDAC3 is a potential validated target for cancer: An overview on the benzamide-based selective HDAC3 inhibitors through comparative SAR\/QSAR\/QAAR approaches"],"prefix":"10.1016","volume":"157","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5523-7716","authenticated-orcid":false,"given":"Nilanjan","family":"Adhikari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sk. Abdul","family":"Amin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prakruti","family":"Trivedi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9996-738X","authenticated-orcid":false,"given":"Tarun","family":"Jha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Balaram","family":"Ghosh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2018.08.081_bib1","doi-asserted-by":"crossref","first-page":"3324","DOI":"10.1021\/jm401877m","article-title":"Discovery of the first N-hydroxycinnamamide-based histone deacetylase 1\/3 dual inhibitors with potent oral antitumor activity","volume":"57","author":"Li","year":"2014","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2018.08.081_bib2","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.molcel.2008.02.030","article-title":"Deletion of histone deacetylase 3 reveals critical roles in S phase progression and DNA damage control","volume":"30","author":"Bhaskara","year":"2008","journal-title":"Mol. Cell."},{"key":"10.1016\/j.ejmech.2018.08.081_bib3","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.ccr.2010.10.022","article-title":"HDAC3 is essential for the maintenance of chromatin structure and genome stability","volume":"18","author":"Bhaskara","year":"2010","journal-title":"Canc. Cell"},{"key":"10.1016\/j.ejmech.2018.08.081_bib4","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.pharmthera.2014.04.004","article-title":"Histone deacetylase inhibitor (HDACI) mechanisms of action: emerging insights","volume":"143","author":"Bose","year":"2014","journal-title":"Pharmacol. Therapeut."},{"key":"10.1016\/j.ejmech.2018.08.081_bib5","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1002\/mc.20373","article-title":"HDAC3 overexpression and colon cancer cell proliferation and differentiation","volume":"47","author":"Spurling","year":"2008","journal-title":"Mol. Carcinog."},{"key":"10.1016\/j.ejmech.2018.08.081_bib6","doi-asserted-by":"crossref","first-page":"13548","DOI":"10.1074\/jbc.M510023200","article-title":"Histone deacetylase 3 (HDAC3) and other class I HDACs regulate colon cell maturation and p21 expression and are deregulated in human colon cancer","volume":"281","author":"Wilson","year":"2006","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ejmech.2018.08.081_bib7","first-page":"5325","article-title":"Green tea polyphenol epigallocatechin 3-gallate, contributes to the degradation of DNMT3A and HDAC3 in HCT 116 human colon cancer cells","volume":"33","author":"Moseley","year":"2013","journal-title":"Anticancer Res."},{"key":"10.1016\/j.ejmech.2018.08.081_bib8","doi-asserted-by":"crossref","first-page":"7097","DOI":"10.1007\/s13277-014-1961-6","article-title":"Stat3 inhibits Beclin 1 expression through recruitment of HDAC3 in nonsmall cell lung cancer cells","volume":"35","author":"Miao","year":"2014","journal-title":"Tumor Biol."},{"key":"10.1016\/j.ejmech.2018.08.081_bib9","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s11010-013-1762-z","article-title":"Histone deacetylases inhibitor trichostatin A increases the expression of Dleu2\/miR-15a\/16-1 via HDAC3 in non-small cell lung cancer","volume":"383","author":"Chen","year":"2013","journal-title":"Mol. Cell. Biochem."},{"key":"10.1016\/j.ejmech.2018.08.081_bib10","doi-asserted-by":"crossref","first-page":"43256","DOI":"10.18632\/oncotarget.9673","article-title":"Xist reduction in breast cancer upregulates AKT phosphorylation via HDAC3-mediated repression of PHLPP1 expression","volume":"7","author":"Huang","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejmech.2018.08.081_bib11","doi-asserted-by":"crossref","first-page":"3499","DOI":"10.1007\/s00018-010-0388-5","article-title":"HDAC3 selectively represses CREB3-mediated transcription and migration of metastatic breast cancer cells","volume":"67","author":"Kim","year":"2010","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.ejmech.2018.08.081_bib12","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1016\/j.chembiol.2017.08.015","article-title":"Divergent JNK phosphorylation of HDAC3 in triple-negative breast cancer cells determines HDAC inhibitor binding and selectivity","volume":"24","author":"Hanigan","year":"2017","journal-title":"Cell. Chem. Biol."},{"key":"10.1016\/j.ejmech.2018.08.081_bib13","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.biopha.2018.01.063","article-title":"I-7ab inhibited the growth of TNBC cells via targeting HDAC3 and promoting the acetylation of p53","volume":"99","author":"Yang","year":"2018","journal-title":"Biomed. Pharma"},{"key":"10.1016\/j.ejmech.2018.08.081_bib14","doi-asserted-by":"crossref","first-page":"56767","DOI":"10.18632\/oncotarget.10790","article-title":"Delphinidin induces apoptosis via cleaved HDAC3-mediated p53 acetylation and oligomerization in prostate cancer cells","volume":"7","author":"Jeong","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejmech.2018.08.081_bib15","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1002\/pros.23467","article-title":"Validation of histone deacetylase 3 as a therapeutic target in castration-resistant prostate cancer","volume":"78","author":"McLeod","year":"2018","journal-title":"Prostate"},{"key":"10.1016\/j.ejmech.2018.08.081_bib16","first-page":"3600","article-title":"Histone deacetylases 3 (HDAC3) is highly expressed in cervical cancer and inhibited by siRNA","volume":"9","author":"Zhang","year":"2016","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"10.1016\/j.ejmech.2018.08.081_bib17","doi-asserted-by":"crossref","first-page":"7747","DOI":"10.18632\/oncotarget.6820","article-title":"HDAC3 mediates smoking-induced pancreatic cancer","volume":"7","author":"Edderkaoui","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejmech.2018.08.081_bib18","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.3892\/ijo.2014.2568","article-title":"Histone deacetylase 3 promotes pancreatic cancer cell proliferation, invasion and increases drug-resistance through histone modification of P27, P53 and Bax","volume":"45","author":"Jiao","year":"2014","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.ejmech.2018.08.081_bib19","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.canlet.2013.07.022","article-title":"Histone deacetylase 3 participates in self-renewal of liver cancer stem cells through histone modification","volume":"339","author":"Liu","year":"2013","journal-title":"Canc. Lett."},{"key":"10.1016\/j.ejmech.2018.08.081_bib20","first-page":"155","article-title":"Histone deacetylase 3 is associated with gastric cancer cell growth via the miR-454-mediated targeting of CHD5","volume":"41","author":"Xu","year":"2018","journal-title":"Int. J. Mol. Med."},{"key":"10.1016\/j.ejmech.2018.08.081_bib21","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1038\/onc.2009.117","article-title":"HDAC3 represses the expression of NKG2D ligands ULBPs in epithelial tumour cells: potential implications for the immunosurveillance of cancer","volume":"28","author":"L\u00f3pez-Soto","year":"2009","journal-title":"Oncogene"},{"key":"10.1016\/j.ejmech.2018.08.081_bib22","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0014460","article-title":"Identification of histone deacetylase 3 as a biomarker for tumor recurrence following liver transplantation in HBV-associated hepatocellular carcinoma","volume":"5","author":"Wu","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2018.08.081_bib23","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/j.biopha.2016.07.049","article-title":"Bakkenolide A inhibits leukemia by regulation of HDAC3 and PI3K\/Akt-related signaling pathways","volume":"83","author":"Zhang","year":"2016","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.ejmech.2018.08.081_bib24","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0115401","article-title":"Ginsenoside Rg3 inhibits melanoma cell proliferation through down-regulation of histone deacetylase 3 (HDAC3) and increase of p53 acetylation","volume":"9","author":"Shan","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2018.08.081_bib25","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1158\/2159-8290.CD-16-0975","article-title":"CREBBP inactivation promotes the development of HDAC3-dependent lymphomas","volume":"7","author":"Jiang","year":"2017","journal-title":"Canc. Discov."},{"key":"10.1016\/j.ejmech.2018.08.081_bib26","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1038\/leu.2017.144","article-title":"HDAC3 regulates DNMT1 expression in multiple myeloma: therapeutic implications","volume":"31","author":"Harada","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.ejmech.2018.08.081_bib27","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1038\/leu.2013.231","article-title":"Histone deacetylase 3 as a novel therapeutic target in multiple myeloma","volume":"28","author":"Minami","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.ejmech.2018.08.081_bib28","doi-asserted-by":"crossref","first-page":"21","DOI":"10.14712\/fb2006052010021","article-title":"Elevated and deregulated expression of HDAC3 in human astrocytic glial tumours","volume":"52","author":"Lib\u00fd","year":"2006","journal-title":"Folia Biol."},{"key":"10.1016\/j.ejmech.2018.08.081_bib29","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1186\/s12906-017-2029-0","article-title":"Coptis Chinensis affects the function of glioma cells through the down-regulation of phosphorylation of STAT3 by reducing HDAC3","volume":"17","author":"Li","year":"2017","journal-title":"BMC Compl. Alternative Med."},{"key":"10.1016\/j.ejmech.2018.08.081_bib30","doi-asserted-by":"crossref","first-page":"7346","DOI":"10.1038\/sj.onc.1208879","article-title":"Inhibition of histone deacetylase 3 stimulates apoptosis induced by heat shock under acidic conditions in human maxillary cancer","volume":"24","author":"Narita","year":"2005","journal-title":"Oncogene"},{"key":"10.1016\/j.ejmech.2018.08.081_bib31","doi-asserted-by":"crossref","first-page":"3131","DOI":"10.1093\/nar\/29.15.3131","article-title":"The histone deacetylase HDAC3 targets RbAp48 to the retinoblastoma protein","volume":"29","author":"Nicolas","year":"2001","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ejmech.2018.08.081_bib32","doi-asserted-by":"crossref","first-page":"99402","DOI":"10.18632\/oncotarget.19660","article-title":"Down-regulation of HDAC3 inhibits growth of cholangiocarcinoma by inducing apoptosis","volume":"8","author":"Zhang","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejmech.2018.08.081_bib33","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1517\/13543784.2010.510514","article-title":"The clinical development of histone deacetylase inhibitors as targeted anticancer drugs","volume":"19","author":"Marks","year":"2010","journal-title":"Expert Opin. Invest. Drugs"},{"key":"10.1016\/j.ejmech.2018.08.081_bib34","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s13148-010-0012-4","article-title":"Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy","volume":"1","author":"Wagner","year":"2010","journal-title":"Clin. Epigenet."},{"key":"10.1016\/j.ejmech.2018.08.081_bib35","doi-asserted-by":"crossref","first-page":"5420","DOI":"10.1038\/sj.onc.1210610","article-title":"Histone deacetylases and cancer","volume":"26","author":"Glozak","year":"2007","journal-title":"Oncogene"},{"key":"10.1016\/j.ejmech.2018.08.081_bib36","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1172\/JCI69738","article-title":"New and emerging HDAC inhibitors for cancer treatment","volume":"124","author":"West","year":"2014","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.ejmech.2018.08.081_bib37","doi-asserted-by":"crossref","first-page":"3112","DOI":"10.1172\/JCI60806","article-title":"HDAC3 is essential for DNA replication in hematopoietic progenitor cells","volume":"123","author":"Summers","year":"2013","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.ejmech.2018.08.081_bib38","doi-asserted-by":"crossref","first-page":"6803","DOI":"10.1021\/acs.jmedchem.5b00545","article-title":"Potent and selective inhibitors of histone deacetylase-3 containing chiral oxazoline capping groups and a N-(2-Aminophenyl)-benzamide binding unit","volume":"58","author":"Marson","year":"2015","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2018.08.081_bib39","doi-asserted-by":"crossref","first-page":"5439","DOI":"10.1038\/sj.onc.1210612","article-title":"HDAC3: taking the SMRT-N-CoRrect road to repression","volume":"26","author":"Karagianni","year":"2007","journal-title":"Oncogene"},{"key":"10.1016\/j.ejmech.2018.08.081_bib40","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1021\/acschembio.5b00640","article-title":"An isochemogenic set of inhibitors to define the therapeutic potential of histone deacetylases in \u03b2-Cell protection","volume":"11","author":"Wagner","year":"2016","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.ejmech.2018.08.081_bib41","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0068915","article-title":"Inhibition of histone deacetylase 3 causes replication stress in cutaneous T cell lymphoma","volume":"8","author":"Wells","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2018.08.081_bib42","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.ejmech.2017.08.069","article-title":"Targeting breast cancer stem cells by novel HDAC3-selective inhibitors","volume":"140","author":"Hsieh","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2018.08.081_bib43","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1101\/gad.244772.114","article-title":"Wnt some lose some: transcriptional governance of stem cells by Wnt\/beta-catenin signaling","volume":"28","author":"Lien","year":"2014","journal-title":"Genes Dev."},{"key":"10.1016\/j.ejmech.2018.08.081_bib44","doi-asserted-by":"crossref","DOI":"10.1038\/oncsis.2017.14","article-title":"Wnt signaling in triple-negative breast cancer","volume":"6","author":"Pohl","year":"2017","journal-title":"Oncogenesis"},{"key":"10.1016\/j.ejmech.2018.08.081_bib45","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1038\/onc.2016.304","article-title":"Wnt signaling in cancer","volume":"36","author":"Zhan","year":"2017","journal-title":"Oncogene"},{"key":"10.1016\/j.ejmech.2018.08.081_bib46","doi-asserted-by":"crossref","first-page":"8641","DOI":"10.1038\/s41598-017-08535-4","article-title":"HDAC3 inhibition ameliorates spinal cord injury by immunomodulation","volume":"7","author":"Kuboyama","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejmech.2018.08.081_bib47","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1523\/JNEUROSCI.5052-10.2011","article-title":"HDAC3 is a critical negative regulator of long-term memory formation","volume":"31","author":"McQuown","year":"2011","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.ejmech.2018.08.081_bib48","doi-asserted-by":"crossref","first-page":"2647","DOI":"10.1073\/pnas.1213364110","article-title":"HDAC3-selective inhibitor enhances extinction of cocaine-seeking behavior in a persistent manner","volume":"110","author":"Malvaez","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.ejmech.2018.08.081_bib49","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1111\/dom.12470","article-title":"Histone deacetylase 3 inhibition improves glycaemia and insulin secretion in obese diabetic rats","volume":"17","author":"Lundh","year":"2015","journal-title":"Diabetes Obes. Metabol."},{"key":"10.1016\/j.ejmech.2018.08.081_bib50","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1136\/annrheumdis-2015-209064","article-title":"Histone deacetylase 3 regulates the inflammatory gene expression programme of rheumatoid arthritis fibroblast-like synoviocytes","volume":"76","author":"Angiolilli","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.ejmech.2018.08.081_bib51","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1161\/CIRCRESAHA.113.301071","article-title":"Histone deacetylase inhibition attenuates transcriptional activity through its acetylation and prevents development of hypertension","volume":"112","author":"Lee","year":"2013","journal-title":"Circ. Res."},{"key":"10.1016\/j.ejmech.2018.08.081_bib52","doi-asserted-by":"crossref","first-page":"L1410","DOI":"10.1152\/ajplung.00180.2015","article-title":"Histone deacetylase inhibitors prevent pulmonary endothelial hyperpermeability and acute lung injury by regulating heat shock protein 90 function","volume":"309","author":"Joshi","year":"2015","journal-title":"Am. J. Lung Cell Mol. Physiol."},{"key":"10.1016\/j.ejmech.2018.08.081_bib53","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1089\/jop.2017.0059","article-title":"Targeting HDAC3 activity with RGFP966 protects against retinal ganglion cell nuclear atrophy and apoptosis after optic nerve injury","volume":"34","author":"Schmitt","year":"2018","journal-title":"J.\u00a0Ocul. Pharmacol. Therapeut."},{"key":"10.1016\/j.ejmech.2018.08.081_bib54","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.kint.2017.02.023","article-title":"Kletho restoration via acetylation of peroxisome proliferation-activated receptor \u03b3 reduces the progression of chronic kidney disease","volume":"92","author":"Lin","year":"2017","journal-title":"Kidney Int."},{"key":"10.1016\/j.ejmech.2018.08.081_bib55","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1084\/jem.20082826","article-title":"Drug inhibition of HDAC3 and epigenetic control of differentiation in Apicomplexa parasites","volume":"206","author":"Bougdour","year":"2009","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.ejmech.2018.08.081_bib56","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1016\/j.jid.2017.04.031","article-title":"Regulation of the glycerol transporter, Aquaporin-3, by histone Deacetylase-3 and p53 in keratinocytes","volume":"137","author":"Choudhary","year":"2017","journal-title":"J.\u00a0Invest. Dermatol."},{"key":"10.1016\/j.ejmech.2018.08.081_bib57","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1002\/cmdc.201300297","article-title":"Histone deacetylase inhibitors with enhanced enzymatic inhibition effects and potent in\u00a0vitro and in\u00a0vivo antitumor activities","volume":"9","author":"Zhang","year":"2014","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2018.08.081_bib58","doi-asserted-by":"crossref","first-page":"4350","DOI":"10.1021\/jm2001025","article-title":"Design, synthesis, docking, and biological evaluation of novel diazide-containing isoxazoleand pyrazole-based histone deacetylase probes","volume":"54","author":"Neelarapu","year":"2011","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2018.08.081_bib59","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1021\/ml300366t","article-title":"Development of N-hydroxycinnamamide-based histone deacetylase inhibitors with an indole-containing cap group","volume":"4","author":"Zhang","year":"2013","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2018.08.081_bib60","doi-asserted-by":"crossref","first-page":"3023","DOI":"10.1016\/j.bmcl.2009.04.058","article-title":"Isoxazole moiety in the linker region of HDAC inhibitors adjacent to the Zn-chelating group: effects on HDAC biology and antiproliferative activity","volume":"19","author":"Tapadar","year":"2009","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2018.08.081_bib61","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.ejmech.2017.01.035","article-title":"Design, synthesis and biological evaluation of thienopyrimidine hydroxamic acid based derivatives as structurally novel histone deacetylase (HDAC) inhibitors","volume":"128","author":"Wang","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2018.08.081_bib62","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.3390\/ijms18071414","article-title":"Histone deacetylase inhibitors as anticancer drugs","volume":"18","author":"Eckschlager","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2018.08.081_bib63","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1021\/ml300371t","article-title":"Biological evaluation of new largazole analogues: alteration of macrocyclic scaffold with click chemistry","volume":"4","author":"Li","year":"2013","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2018.08.081_bib64","doi-asserted-by":"crossref","first-page":"3252","DOI":"10.1016\/j.bmc.2010.03.022","article-title":"Synthesis and biological activity of cyclotetrapeptide analogues of the natural HDAC inhibitor FR235222","volume":"18","author":"Terracciano","year":"2010","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2018.08.081_bib65","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1021\/jm101373a","article-title":"Oxime amides as a novel zinc binding group in histone deacetylase inhibitors: synthesis, biological activity, and computational evaluation","volume":"54","author":"Botta","year":"2011","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2018.08.081_bib66","doi-asserted-by":"crossref","first-page":"2589","DOI":"10.1021\/acs.jmedchem.8b00136","article-title":"Class I HDAC inhibitors display different antitumor mechanism in leukemia and prostatic cancer cells depending on their p53 status","volume":"61","author":"Li","year":"2018","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2018.08.081_bib67","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.chembiol.2014.12.015","article-title":"Identification of HDAC inhibitors with benzoylhydrazide scaffold that selectively inhibit class I HDACs","volume":"22","author":"Wang","year":"2015","journal-title":"Chem. Biol."},{"key":"10.1016\/j.ejmech.2018.08.081_bib68","doi-asserted-by":"crossref","first-page":"9942","DOI":"10.1021\/acs.jmedchem.6b01385","article-title":"Development of allosteric hydrazide-containing class I histone deacetylase inhibitors for use in acute myeloid leukemia","volume":"59","author":"McClure","year":"2016","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2018.08.081_bib69","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0068669","article-title":"Identification of highly selective and potent histone deacetylase 3 inhibitors using click chemistry-based combinatorial fragment assembly","volume":"8","author":"Suzuki","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2018.08.081_bib70","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2016.457","article-title":"Histone deacetylase 3 overexpression in human cholangiocarcinoma and promotion of cell growth via apoptosis inhibition","volume":"8","author":"Yin","year":"2017","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.ejmech.2018.08.081_bib71","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1021\/jm901667k","article-title":"Synthesis and biological evaluation of triazol-4-ylphenyl-bearing histone deacetylase inhibitors as anticancer agents","volume":"53","author":"He","year":"2010","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2018.08.081_bib72","doi-asserted-by":"crossref","first-page":"3276","DOI":"10.1021\/acs.organomet.7b00437","article-title":"An HDAC3-selective ferrocene analogue with remarkably enhanced redox-triggered ferrocenium activity in cells","volume":"36","author":"Ocasio","year":"2017","journal-title":"Organometallics"},{"key":"10.1016\/j.ejmech.2018.08.081_bib73","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1021\/acschembio.7b00321","article-title":"Comparison of the deacylase and deacetylase activity of zinc-dependent HDACs","volume":"12","author":"McClure","year":"2017","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.ejmech.2018.08.081_bib74","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.conb.2014.03.008","article-title":"HDAC signaling in neuronal development and axon regeneration","volume":"27","author":"Cho","year":"2014","journal-title":"Curr. Opin. Neurobiol."},{"key":"10.1016\/j.ejmech.2018.08.081_bib75","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.bbrc.2007.03.010","article-title":"Sequence and expression analysis of histone deacetylases in rice","volume":"356","author":"Fu","year":"2007","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ejmech.2018.08.081_bib76","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/S0168-9525(03)00073-8","article-title":"Class II histone deacetylases: versatile regulators","volume":"19","author":"Verdin","year":"2003","journal-title":"Trends Genet."},{"key":"10.1016\/j.ejmech.2018.08.081_bib77","doi-asserted-by":"crossref","first-page":"17335","DOI":"10.1073\/pnas.0706487104","article-title":"Unraveling the hidden catalytic activity of vertebrate class IIa histone deacetylases","volume":"104","author":"Lahm","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U S A."},{"key":"10.1016\/j.ejmech.2018.08.081_bib78","doi-asserted-by":"crossref","first-page":"4389","DOI":"10.1073\/pnas.0430973100","article-title":"Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation","volume":"100","author":"Haggarty","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U S A."},{"key":"10.1016\/j.ejmech.2018.08.081_bib79","doi-asserted-by":"crossref","first-page":"25748","DOI":"10.1074\/jbc.M111871200","article-title":"Cloning and functional characterization of HDAC11, a novel member of the human histone deacetylase family","volume":"277","author":"Gao","year":"2002","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ejmech.2018.08.081_bib80","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1042\/CS20120504","article-title":"Histone deacetylases as targets for treatment of multiple diseases","volume":"124","author":"Tang","year":"2013","journal-title":"Clin. Sci. (Lond.)"},{"key":"10.1016\/j.ejmech.2018.08.081_bib81","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1042\/BJ20150660","article-title":"Histone deacetylase 3 indirectly modulates tubulin acetylation","volume":"472","author":"Bacon","year":"2015","journal-title":"Biochem. J."},{"key":"10.1016\/j.ejmech.2018.08.081_bib82","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1126\/science.272.5260.408","article-title":"A\u00a0mammalian histone deacetylase related to the yeast transcriptional regulator Rpd3p","volume":"272","author":"Taunton","year":"1996","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2018.08.081_bib83","doi-asserted-by":"crossref","first-page":"12845","DOI":"10.1073\/pnas.93.23.12845","article-title":"Transcriptional repression by YY1 is mediated by interaction with a mammalian homolog of the yeast global regulator RPD3","volume":"93","author":"Yang","year":"1996","journal-title":"Proc. Natl. Acad. Sci. U S A."},{"key":"10.1016\/j.ejmech.2018.08.081_bib84","doi-asserted-by":"crossref","first-page":"28001","DOI":"10.1074\/jbc.272.44.28001","article-title":"Isolation and characterization of cDNAs corresponding to an additional member of the human histone deacetylase gene family","volume":"272","author":"Yang","year":"1997","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ejmech.2018.08.081_bib85","doi-asserted-by":"crossref","first-page":"634","DOI":"10.3390\/ph7060634","article-title":"Involvement of HDAC1 and HDAC3 in the pathology of polyglutamine disorders: therapeutic implications for selective HDAC1\/HDAC3 inhibitors","volume":"7","author":"Thomas","year":"2014","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.ejmech.2018.08.081_bib86","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/BF02686117","article-title":"Distribution of histone deacetylases 1-11 in the rat brain","volume":"31","author":"Broide","year":"2007","journal-title":"J.\u00a0Mol. Neurosci."},{"key":"10.1016\/j.ejmech.2018.08.081_bib87","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1038\/leu.2017.3","article-title":"HDAC3 activity is required for initiation of leukemogenesis in acute promyelocytic leukemia","volume":"31","author":"Mehdipour","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.ejmech.2018.08.081_bib88","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.ccr.2012.09.003","article-title":"Coordinated silencing of MYC-mediated miR-29 by HDAC3 and EZH2 as a therapeutic target of histone modification in aggressive B-Cell lymphomas","volume":"22","author":"Zhang","year":"2012","journal-title":"Canc. Cell"},{"key":"10.1016\/j.ejmech.2018.08.081_bib89","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1002\/ijc.25151","article-title":"Type-specific roles of histone deacetylase (HDAC) overexpression in ovarian carcinoma: HDAC1 enhances cell proliferation and HDAC3 stimulates cell migration with downregulation of E-cadherin","volume":"127","author":"Hayashi","year":"2010","journal-title":"Int. J. Canc."},{"key":"10.1016\/j.ejmech.2018.08.081_bib90","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.brainres.2013.04.061","article-title":"Histone deacetylase 3 implicated in the pathogenesis of children glioma by promoting glioma cell proliferation and migration","volume":"1520","author":"Zhu","year":"2013","journal-title":"Brain Res."},{"key":"10.1016\/j.ejmech.2018.08.081_bib91","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.bbrc.2010.04.089","article-title":"Suppression of histone deacetylase 3 (HDAC3) enhances apoptosis induced by paclitaxel in human maxillary cancer cells in\u00a0vitro and in\u00a0vivo","volume":"396","author":"Narita","year":"2010","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ejmech.2018.08.081_bib92","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.4155\/fmc-2017-0130","article-title":"Structure-activity relationships of hydroxamate-based histone deacetylase-8 inhibitors: reality behind anticancer drug discovery","volume":"9","author":"Amin","year":"2018","journal-title":"Future Med. Chem."},{"key":"10.1016\/j.ejmech.2018.08.081_bib93","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1634\/theoncologist.12-10-1247","article-title":"FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma","volume":"12","author":"Mann","year":"2007","journal-title":"Oncol"},{"key":"10.1016\/j.ejmech.2018.08.081_bib94","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.jsb.2016.06.023","article-title":"Structure of \u2018linkerless\u2019 hydroxamic acid inhibitor-HDAC8 complex confirms the formation of an isoform-specific subpocket","volume":"195","author":"Tabackman","year":"2016","journal-title":"J.\u00a0Struct. Biol."},{"key":"10.1016\/j.ejmech.2018.08.081_bib95","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1158\/1078-0432.CCR-14-3119","article-title":"FDA approval: belinostat for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma","volume":"21","author":"Lee","year":"2015","journal-title":"Clin. Canc. Res."},{"key":"10.1016\/j.ejmech.2018.08.081_bib96","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1093\/jnci\/djv165","article-title":"FDA approves new agent for multiple myeloma","volume":"107","author":"Fenichel","year":"2015","journal-title":"J.\u00a0Natl. Cancer Inst."},{"key":"10.1016\/j.ejmech.2018.08.081_bib97","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.phrs.2017.05.002","article-title":"Is dual inhibition of metalloenzymes HDAC-8 and MMP-2 a potential pharmacological target to combat hematological malignancies?","volume":"122","author":"Amin","year":"2017","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.ejmech.2018.08.081_bib98","doi-asserted-by":"crossref","first-page":"185","DOI":"10.5582\/irdr.2016.01024","article-title":"Development of chidamide for peripheral T-cell lymphoma, the first orphan drug approved in China","volume":"5","author":"Lu","year":"2016","journal-title":"Intractable Rare Dis. Res."},{"key":"10.1016\/j.ejmech.2018.08.081_bib99","doi-asserted-by":"crossref","first-page":"5543","DOI":"10.1021\/jm701079h","article-title":"Novel aminophenyl benzamide-type histone deacetylase inhibitors with enhanced potency and selectivity","volume":"50","author":"Moradei","year":"2007","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2018.08.081_bib100","doi-asserted-by":"crossref","first-page":"39","DOI":"10.3727\/096504005775082066","article-title":"In\u00a0vitro study of CI-994, a histone deacetylase inhibitor, in non-small cell lung cancer cell lines","volume":"15","author":"Loprevite","year":"2005","journal-title":"Oncol. Res."},{"key":"10.1016\/j.ejmech.2018.08.081_bib101","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/BF00180810","article-title":"Preclinical antitumor activity of CI-994","volume":"14","author":"LoRusso","year":"1996","journal-title":"Invest. N. Drugs"},{"key":"10.1016\/j.ejmech.2018.08.081_bib102","first-page":"1517","article-title":"CI-994 (N-acetyl-dinaline) in combination with conventional anti-cancer agents is effective against acute myeloid leukemia in\u00a0vitro and in\u00a0vivo","volume":"19","author":"Hubeek","year":"2008","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.ejmech.2018.08.081_bib103","doi-asserted-by":"crossref","first-page":"3192","DOI":"10.1007\/s11064-016-2043-5","article-title":"Histone deacetylase Inhibitor RGFP109 overcomes temozolomide resistance by blocking NF-\u03baB-dependent transcription in glioblastoma cell lines","volume":"41","author":"Li","year":"2016","journal-title":"Neurochem. Res."},{"key":"10.1016\/j.ejmech.2018.08.081_bib104","doi-asserted-by":"crossref","first-page":"7597","DOI":"10.1016\/j.bmc.2015.11.005","article-title":"Design, synthesis and evaluation of antiestrogen and histone deacetylase inhibitor molecular hybrids","volume":"23","author":"Mendoza-Sanchez","year":"2015","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2018.08.081_bib105","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1007\/s11523-016-0444-7","article-title":"Evaluation of the therapeutic potential of the novel isotype specific HDAC inhibitor 4SC-202 in urothelial carcinoma cell lines","volume":"11","author":"Pinkerneil","year":"2016","journal-title":"Targeted Oncol."},{"key":"10.1016\/j.ejmech.2018.08.081_bib106","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1517\/13543784.2011.613822","article-title":"Entinostat for treatment of solid tumors and hematologic malignancies","volume":"20","author":"Knipstein","year":"2011","journal-title":"Expet Opin. Invest. Drugs"},{"key":"10.1016\/j.ejmech.2018.08.081_bib107","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1002\/ddr.20167","article-title":"The histone deacetylase inhibitor MS-275 induces p21WAF1\/Cip1 expression in human Hep3B hepatoma cells","volume":"68","author":"Zhang","year":"2007","journal-title":"Drug Dev. Res."},{"key":"10.1016\/j.ejmech.2018.08.081_bib108","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1016\/j.leukres.2012.07.002","article-title":"Induction of differentiation and apoptosis in leukaemic cell lines by the novel benzamide family histone deacetylase 2 and 3 inhibitor MI-192","volume":"36","author":"Boissinot","year":"2012","journal-title":"Leuk. Res."},{"key":"10.1016\/j.ejmech.2018.08.081_bib109","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1042\/BJ20070779","article-title":"Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors","volume":"409","author":"Khan","year":"2008","journal-title":"Biochem. J."},{"key":"10.1016\/j.ejmech.2018.08.081_bib110","doi-asserted-by":"crossref","first-page":"3928","DOI":"10.1016\/j.bmcl.2009.03.085","article-title":"Design and synthesis of novel hybrid benzamide-peptide histone deacetylase inhibitors","volume":"19","author":"Hu","year":"2009","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2018.08.081_bib111","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1016\/j.bmc.2017.03.036","article-title":"Design, synthesis and anti-tumor activity study of novel histone deacetylase inhibitors containing isatin-based caps and o-phenylenediamine-based zinc binding groups","volume":"25","author":"Gao","year":"2017","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2018.08.081_bib112","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.ejmech.2017.03.069","article-title":"Selective HDAC inhibitors with potent oral activity against leukemia and colorectal cancer: design, structure-activity relationship and anti-tumor activity study","volume":"134","author":"Li","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2018.08.081_bib113","doi-asserted-by":"crossref","first-page":"6156","DOI":"10.1021\/jm400634n","article-title":"Discovery of potent, isoform-selective inhibitors of histone deacetylase containing chiral heterocyclic capping groups and a N-(2-aminophenyl)benzamide binding unit","volume":"56","author":"Marson","year":"2013","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2018.08.081_bib114","first-page":"1","article-title":"Designing potential HDAC-3 inhibitors to improve memory and learning","author":"Amin","year":"2018","journal-title":"J.\u00a0Biomol. Struct. Dynam."},{"key":"10.1016\/j.ejmech.2018.08.081_bib115","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1104\/pp.26.2.369","article-title":"The relationship of structure and plant-growth activity of substituted benzoic and phenoxyacetic acids","volume":"26","author":"Muir","year":"1951","journal-title":"Plant Physiol"},{"key":"10.1016\/j.ejmech.2018.08.081_bib116","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1021\/jm00377a009","article-title":"Structure-activity relationship of the ficin hydrolysis of phenyl hippurates. Comparison with papain, actinidin, and bromelain","volume":"27","author":"Carotti","year":"1984","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2018.08.081_bib117","first-page":"23","article-title":"Comparative structure-activity relationships","volume":"291","author":"Hansch","year":"1989","journal-title":"Prog. Clin. Biol. Res."},{"key":"10.1016\/j.ejmech.2018.08.081_bib118","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/0048-9697(91)90167-D","article-title":"Structure-activity relationships of chemical mutagens and carcinogens","volume":"109\u2013110","author":"Hansch","year":"1991","journal-title":"Sci. Total Environ."},{"key":"10.1016\/j.ejmech.2018.08.081_bib119","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ejmech.2017.02.014","article-title":"Arylsulfonamides and selectivity of matrix metalloproteinase-2: an overview","volume":"129","author":"Adhikari","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2018.08.081_bib120","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1021\/cr9400976","article-title":"Comparative QSAR: toward a deeper understanding of chemicobiological interactions","volume":"96","author":"Hansch","year":"1996","journal-title":"Chem. Rev."},{"key":"10.1016\/j.ejmech.2018.08.081_bib121","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1021\/cr0102009","article-title":"Chem-bioinformatics: comparative QSAR at the interface between chemistry and biology","volume":"102","author":"Hansch","year":"2002","journal-title":"Chem. Rev."},{"key":"10.1016\/j.ejmech.2018.08.081_bib122","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1081\/DMR-120028428","article-title":"QSAR of cytochrome P450","volume":"36","author":"Hansch","year":"2004","journal-title":"Drug Metab. Rev."},{"key":"10.1016\/j.ejmech.2018.08.081_bib123","doi-asserted-by":"crossref","first-page":"3391","DOI":"10.1016\/j.bmc.2003.11.037","article-title":"QSAR and ADME","volume":"12","author":"Hansch","year":"2004","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2018.08.081_bib124","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/j.bmc.2004.10.064","article-title":"Chemical-biological interactions in human","volume":"13","author":"Verma","year":"2005","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2018.08.081_bib125","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/s10822-011-9444-y","article-title":"The advent and evolution of QSAR at Pomona College","volume":"25","author":"Hansch","year":"2011","journal-title":"J.\u00a0Comput. Aided Mol. Des."},{"key":"10.1016\/j.ejmech.2018.08.081_bib126","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1021\/cr0780210","article-title":"Camptothecins: a SAR\/QSAR study","volume":"109","author":"Verma","year":"2009","journal-title":"Chem. Rev."},{"key":"10.1016\/j.ejmech.2018.08.081_bib127","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/0378-4274(95)03356-P","article-title":"The expanding role of quantitative structure-activity relationships (QSAR) in toxicology","volume":"79","author":"Hansch","year":"1995","journal-title":"Toxicol. Lett."},{"key":"10.1016\/j.ejmech.2018.08.081_bib128","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.ejmech.2017.05.041","article-title":"Combating breast cancer with non-steroidal aromatase inhibitors (NSAIs): understanding the chemico-biological interactions through comparative SAR\/QSAR study","volume":"137","author":"Adhikari","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2018.08.081_bib129","doi-asserted-by":"crossref","first-page":"6427","DOI":"10.1021\/cr500483r","article-title":"QSAR studies on hydroxamic acids: a fascinating family of chemicals with a wide spectrum of activities","volume":"115","author":"Gupta","year":"2015","journal-title":"Chem. Rev."},{"key":"10.1016\/j.ejmech.2018.08.081_bib130","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s11224-017-1028-6","article-title":"Exploring in house glutamate inhibitors of matrix metalloproteinase-2 through validated robust chemico-biological quantitative approaches","volume":"29","author":"Adhikari","year":"2018","journal-title":"Struct. Chem."},{"key":"10.1016\/j.ejmech.2018.08.081_bib131","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s11030-017-9789-9","article-title":"An integrated QSAR modeling approach to explore the structure-property and selectivity relationships of N-benzoyl-L-biphenylalanines as integrin antagonists","volume":"22","author":"Amin","year":"2018","journal-title":"Mol. Divers."},{"key":"10.1016\/j.ejmech.2018.08.081_bib132","doi-asserted-by":"crossref","first-page":"6702","DOI":"10.1039\/C3RA46861E","article-title":"Exploring structural requirements of leads for improving activity and selectivity against CDK5\/p25 in Alzheimer's disease: an in silico approach","volume":"4","author":"Ambure","year":"2014","journal-title":"RSC Adv."},{"key":"10.1016\/j.ejmech.2018.08.081_bib133","series-title":"SYBYL-X 2.0, 1699 South Hanley Road","author":"Tripos Inc","year":"2012"},{"key":"10.1016\/j.ejmech.2018.08.081_bib134","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.bmcl.2007.12.031","article-title":"Exploration of the internal cavity of histone deacetylase (HDAC) with selective HDAC1\/HDAC2 inhibitors (SHI-1:2)","volume":"18","author":"Methot","year":"2008","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2018.08.081_bib135","doi-asserted-by":"crossref","first-page":"6104","DOI":"10.1016\/j.bmcl.2008.10.052","article-title":"SAR profiles of spirocyclic nicotinamide derived selective HDAC1\/HDAC2 inhibitors (SHI-1:2)","volume":"18","author":"Methot","year":"2008","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2018.08.081_bib136","doi-asserted-by":"crossref","first-page":"5300","DOI":"10.1016\/j.bmcl.2007.08.023","article-title":"The discovery of 6-amino nicotinamides as potent and selective histone deacetylase inhibitors","volume":"17","author":"Hamblett","year":"2007","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2018.08.081_bib137","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1002\/cmdc.200800461","article-title":"Studies of benzamide- and thiol-based histone deacetylase inhibitors in models of oxidative-stress- induced neuronal death: identification of some HDAC3-selective inhibitors","volume":"4","author":"Chen","year":"2009","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2018.08.081_bib138","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S1074-5521(02)00305-8","article-title":"A\u00a0fluorogenic histone deacetylase assay well suited for high-throughput activity screening","volume":"10","author":"Wegener","year":"2003","journal-title":"Chem. Biol."},{"key":"10.1016\/j.ejmech.2018.08.081_bib139","first-page":"601","article-title":"First non-radioactive assay for in\u00a0vitro screening of histone deacetylase inhibitors","volume":"55","author":"Hoffman","year":"2000","journal-title":"Pharmazie"},{"key":"10.1016\/j.ejmech.2018.08.081_bib140","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.ejmech.2015.03.035","article-title":"Design, synthesis and biological evaluation of colchicine derivatives as novel tubulin and histone deacetylase dual inhibitors","volume":"95","author":"Zhang","year":"2015","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2018.08.081_bib141","series-title":"Inhibitors of Histone Deacetylase","author":"Mazitschek","year":"2015"},{"key":"10.1016\/j.ejmech.2018.08.081_bib142","series-title":"Fluorescent Substrates for Determining Lysine Modifying Enzyme Activity","author":"Zhang","year":"2013"}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523418307530?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523418307530?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T13:57:46Z","timestamp":1759327066000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523418307530"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":142,"alternative-id":["S0223523418307530"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2018.08.081","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2018,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"HDAC3 is a potential validated target for cancer: An overview on the benzamide-based selective HDAC3 inhibitors through comparative SAR\/QSAR\/QAAR approaches","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2018.08.081","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}